Table 3.
Multi-disciplinary management of 65 cases with breast cancer diagnosed during pregnancy
| Characteristic | N (%) |
|---|---|
| Trimester at diagnosis | |
| 1 | 26 (40%) |
| 2 | 13 (20%) |
| 3 | 17 (26%) |
| Missing | 9 (14%) |
| Obstetric outcome | |
| Elective termination | 7 (11%) |
| Spontaneous abortion | 4 (6%)b |
| Pre-term delivery | 9 (14%) |
| Term delivery | 7 (11%) |
| Post-dates delivery | 1 (2%) |
| Missing | 37 (57%) |
| BCa therapy during pregnancy | |
| Chemotherapy | 20 (31%)c |
| Endocrine therapy | 0 (0%) |
| Radiation | 0 (0%) |
| HER2‒targeted therapy | 0 (0%) |
| Surgery | 20 (31%) |
| Sequencing of BC treatment and delivery | |
| Delivery → Cancer therapy | 10 (15%) |
| Breast cancer surgery → Delivery ± → Adjuvant systemic therapy | 8 (12%) |
| Neoadjuvant chemotherapy → Delivery ± → Further breast cancer therapy | 8 (12%) |
| Breast cancer surgery → Adjuvant chemotherapy → Delivery ± → Further adjuvant systemic therapy | 12 (18%) |
| Missing | 27 (42%) |
| Maternal complications | |
| Infection | 2 (3%)c,d |
| Pre-eclampsia | 3 (5%) |
| Hemorrhage | 1 (2%) |
| Fetal/neonatal complications | |
| Intrauterine growth retardation | 1 (2%)c |
| Malpresentation | 2 (3%) |
| Cytopenias at birth | 1 (2%)e |
a
BC breast cancer
b
One spontaneous abortion occurred during AC
c
Only the percentage of BC-P cases who received each type of treatment during pregnancy or in whom each type of complication occurred is reported
d
One maternal infection occurred during AC
e
The neonate with cytopenias at birth was born to a mother receiving AC